TNF-α is associated with low phase angle in male patients with chronic hepatitis C

Thais Pontello de Vries1, Aline Marcos Pires1, Fernanda Gomes Camilo2

  • 1Sciences Applied to Adult Health Care Post-Graduate Programme, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil; Outpatient Clinic of Viral Hepatitis, Instituto Alfa de Gastroenterologia, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.

Insights

Phase angle (PhA) may indicate systemic inflammation in male chronic hepatitis C (CHC) patients. Lower PhA correlates with higher tumour necrosis factor alpha (TNF-α) levels, suggesting PhA

Area of Science:

  • Hepatology and Immunology
  • Biomarker Discovery
  • Nutritional Science

Background:

  • The role of Phase angle (PhA) as a systemic inflammation biomarker in chronic hepatitis C (CHC) is not well understood.
  • Identifying reliable biomarkers for inflammation and nutritional status in CHC is crucial for patient management.

Purpose of the Study:

  • To investigate the association between PhA values and tumour necrosis factor alpha (TNF-α) in CHC patients.
  • To explore correlations between PhA and demographic, clinical, nutritional, and biochemical factors in CHC.

Main Methods:

  • Cross-sectional study of 81 CHC patients (mean age 50.0 ± 11.7 years).
  • Body composition assessed via anthropometry and bioelectrical impedance analysis (BIA).
  • Serum TNF-α measured by ELISA; logistic regression used for analysis.

Main Results:

  • Reduced PhA was found in 14.8% of CHC patients.
  • In male patients, reduced PhA was independently linked to elevated TNF-α levels (OR: 1.21; 95% CI: 1.06-1.39).
  • No significant association between PhA and TNF-α was observed in female patients.

Conclusions:

  • Lower PhA values in male CHC patients are associated with elevated TNF-α levels, irrespective of liver disease severity.
  • PhA shows potential as a practical screening tool for systemic inflammation and nutritional risk in CHC.
  • Integrating PhA assessment into routine care could benefit healthcare settings for CHC patients.
Abstract

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...